Drugs / WT1 derived peptides
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00672152 | Jun 2007 → Apr 2013 | B-cell neoplasm, acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia +1 | Michael Morse, MD | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WT1 derived peptides | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00672152 ↗ |
| Action | Activate | “These peptides are intended to be given as a "vaccine" to activate the immune cells in a person to attack his/her cancer.” NCT00672152 ↗ |
| Modality | Vaccine | “These peptides are intended to be given as a "vaccine" to activate the immune cells in a person to attack his/her cancer.” NCT00672152 ↗ |